Track RNXT and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$31.50M
Enterprise Value$24.60M
Revenue (TTM)$1.12M
Net Income (TTM)-$11.17M
Free Cash Flow (TTM)-$10.97M
Financial Health
Cash$7.02M
Net Debt-$6.90M
Debt Ratio0.02
Debt to Equity0.02
Interest Coverage-
Valuation (TTM)
Price to Sales28.05
Price to Earnings-2.82
EV to EBITDA-2.13
Price to Book5.81
Price to Free Cash Flow-2.87
Margins (TTM)
Gross Profit Margin70.88%
EBITDA Margin-1026.45%
Operating Income Margin-1113.98%
Net Income Margin-994.48%
Free Cash Flow Margin-977.29%
Returns (5Y Avg)
Return on Invested Capital-10.79%
Return on Assets-276.57%
Return on Equity-52.30%
Return on Total Capital-10.79%
Return on Capital Employed-899.04%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue1000.00%
Diluted EPS20.87%
Total Debt-94.86%
Capital Expenditures-33.16%
Free Cash Flow-95.78%
CAGR (3Y)
Revenue1000.00%
Diluted EPS20.89%
Total Debt0.00%
Capital Expenditures1000.00%
Free Cash Flow-99.23%
CAGR (1Y)
Revenue1000.00%
Diluted EPS8.15%
Total Debt-100.00%
Capital Expenditures-83.33%
Free Cash Flow-100.00%
$0.88+$0.01|+1.58%
Last updated: Jul 21, 4:00 PM ET
52W High$1.45
52W Low$0.70
50D SMA$0.89
200D SMA$0.96
Volume117.38K
RenovoRx Inc
2570 West El Camino Real, Mountain View, CA, United States, 94040
IPO
2021
Employees
17
Industry
Biotechnology
Sector
Healthcare
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20260+1
1
Q4 20250+7
7
Q3 20250+2
2
Q2 20250+1
1
4-quarter cumulative
0 sells11 buys
Analyst Ratings
2 analysts covering
Buy100%recommend buy
Buy
2
Hold
0
Sell
0